MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
QIA.DE stock logo

QIA.DE

Qiagen N.V.

$29.04
0.53
 (1.84%)
[ms_data_label text=’Delayed data’]
Exchange:  XETRA
Market Cap:  5.983B
Shares Outstanding:  215.001M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Diagnostics & Research
   
CEO:  Thierry L. Bernard
Full Time Employees:  5700
Address: 
Hulsterweg 82
Venlo
5912 PL
NL
Website:  https://www.qiagen.com
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,965,3111,978,2142,090,141.356
Gross Profit1,233,6881,324,7911,291,582.967
EBITDA688,555702,067717,315.854
Operating Income409,93897,711520,345.439
Net Income341,30383,591424,908.939

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets6,115,1905,689,6226,296,390.839
Total Liabilities2,307,4262,122,2832,517,979.496
Total Stockholders Equity3,807,7643,567,3393,778,411.342
Total Debt1,532,0621,512,5411,654,540.688
Cash and Cash Equivalents668,084663,555839,062.147

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow459,455673,551654,370.568
Capital Expenditure-162,802-167,174-201,062.693
Free Cash Flow296,653506,377453,307.874
Net Income341,30383,591424,908.939
Net Change in Cash-62,585-4,52986,173.807

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)2,700,959.660Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)2,765,779.315Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)2,721,389.369Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)977,727.014Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)1,001,191.240Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)985,122.414Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)715,353.638Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)737,723.385Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)722,404.745Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)756,722.305Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)774,882.695Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)762,446.055Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)3.470Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)3.550Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)3.440Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)15Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)2Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
4.07
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
20.17
?Enterprise Value
 (TTM)
: 
9.314B  ?EV/FCF
 (TTM)
: 
20.58
?Dividend Yield
 (TTM)
: 
0.06  ?Payout Ratio
 (TTM)
: 
0.13
?ROE
 (TTM)
: 
0.12  ?ROIC
 (TTM)
: 
0.08
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.44
?P/B
 (TTM)
: 
2.27  ?Current Ratio
 (TTM)
: 
3.9

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
11.76Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate QIA Intrinsic Value

Common questions about QIA.DE valuation

Is Qiagen N.V. (QIA.DE) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Qiagen N.V. (QIA.DE) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is QIA.DE a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether QIA.DE trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is QIA.DE’s P/E ratio?

You can see QIA.DE’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for QIA.DE?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is QIA.DE a good long-term investment?

Whether QIA.DE fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

QIA.DE

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

1.84
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low: 28.27   Year High: 47.6
Price Avg 50: 35.93   Price Avg 200: 40.82
Volume: 736416   Average Volume: 573822

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
Could not create stock discussion for QIA

Relevant news

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read